EXHIBIT 99.1

EDG Capital, Inc. Announces Resumption of Clinical Trial of P32/MAA in Brain
Cancer.

NEW YORK, February 13, 2001 - EDG Capital, Inc. (OTCBB: EDGN), a developer of
nuclear pharmaceuticals for therapeutic use in the treatment of cancer, today
announced that effective immediately it is resuming clinical trials of Colloidal
(32)P Phosphorus and Macroaggregated Albumin (P32/MAA) in the treatment of brain
cancer. As announced earlier, the Food and Drug Administration (FDA) had asked
for assurances that the P32 and MAA products meet a specific endotoxin purity
requirement before enrollment of patients into the brain cancer study could
continue. The supplier of these products has agreed to take the necessary steps
that will enable the company to comply with the FDA requirements.

"We are very pleased to continue with enrollment of patients in our P32/MAA
clinical study of brain cancer," said Jack Schwartzberg, Chief Executive
Officer, President and Chairman of EDG Capital. "Accruing patients for both our
brain tumor and pancreatic cancer programs will serve to bring us closer to our
goal of commercializing our patented P32/MAA procedure."

About EDG Capital, Inc. Through its wholly-owned subsidiary, Isotope Solutions,
Inc., EDG Capital is engaged in the research, development and testing of nuclear
pharmaceuticals for therapeutic use in the treatment of the most lethal forms of
cancer. Internationally renowned clinicians, who are under management contracts
with Isotope Solutions Inc., conduct research for the company.

Legal Disclaimers: This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results of operations may differ materially from those projected or suggested in
the forward-looking statements. The forward-looking statements contained herein
represent EDG Capital, Inc.'s judgment as of the date of this release, and EDG
Capital, Inc. cautions investors not to place undue reliance on such statements.

CONTACT:   EDG Capital, Inc., New York
           Shragie David Aranoff
           Vice President
           516/222-5154
           shragie@isotopesolutions.com

           or


                                       4


           Rubenstein Associates, Inc.
           Patricia Amerman
           Vice President
           212/843-8049
           pamerm@rubenstein.com


                                       5